亚洲制服欧美另类-午夜激情av电影-日本高清中文字幕一区二区三区-中国欧美日韩一区二区三区-欧洲亚洲日本韩国-成人欧美激情一区二区-亚洲偷偷自拍高清

掃碼關(guān)注公眾號           掃碼咨詢技術(shù)支持           掃碼咨詢技術(shù)服務(wù)
  
客服熱線:400-901-9800  客服QQ:4009019800  技術(shù)答疑  技術(shù)支持  質(zhì)量反饋  關(guān)于我們  聯(lián)系我們
久久久久久久久性潮,亚洲一级Av无码毛片久久精品
首頁 > 產(chǎn)品中心 > 標記一抗 > 產(chǎn)品信息
Rabbit Anti-Phospho-BRCA1 (Ser1466)/Cy7 Conjugated antibody (bs-12887R-Cy7)
訂購熱線:400-901-9800
訂購郵箱:sales@bioss.com.cn
訂購QQ:  400-901-9800
技術(shù)支持:techsupport@bioss.com.cn
說 明 書: 100ul  
100ul/2980.00元
大包裝/詢價
產(chǎn)品編號 bs-12887R-Cy7
英文名稱 Rabbit Anti-Phospho-BRCA1 (Ser1466)/Cy7 Conjugated antibody
中文名稱 Cy7標記的磷酸化乳腺癌易感基因1抗體
別    名 BRCA1 (phospho S1466); BRCA1 (phospho Ser1466); p-BRCA1 (S1466); p-BRCA1 (Ser1466); p-BRCA1 (phospho S1466); BRCA1(Phospho-Ser1423); BRCA 1; BRCA1; BRCA1/BRCA2 containing complex subunit 1; BRCA1/BRCA2-containing complex, subunit 1; BRCA1_HUMAN; BRCAI; BRAC 1; BRCA 1; BRCC 1; BRCC1; Breast Cancer 1; Breast Cancer 1 Early Onset; Breast cancer type 1 susceptibility protein; Breast and ovarian cancer susceptibility protein 1; Breast Ovarian Cancer Susceptibility; IRIS; Papillary Serous Carcinoma Of The Peritoneum; PSCP; RING finger protein 53; BROVCA1; IRIS; PNCA4; PPP1R53; Protein phosphatase 1 regulatory subunit 53; RNF53; BAP1.   
規(guī)格價格 100ul/2980元 購買        大包裝/詢價
說 明 書 100ul  
產(chǎn)品類型 磷酸化抗體 
研究領(lǐng)域 腫瘤  細胞生物  信號轉(zhuǎn)導(dǎo)  細胞凋亡  
抗體來源 Rabbit
克隆類型 Polyclonal
交叉反應(yīng) (predicted: Human, Horse, )
產(chǎn)品應(yīng)用
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量 208kDa
性    狀 Lyophilized or Liquid
濃    度 1mg/ml
免 疫 原 KLH conjugated Synthesised phosphopeptide derived from human BRCA1 around the phosphorylation site of Ser1466
亞    型 IgG
純化方法 affinity purified by Protein A
儲 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
產(chǎn)品介紹 background:
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified. [provided by RefSeq, May 2009].

Function:
E3 ubiquitin-protein ligase that specifically mediatesthe formation of 'Lys-6'-linked polyubiquitin chains and plays acentral role in DNA repair by facilitating cellular responses toDNA damage. It is unclear whether it also mediates the formation ofother types of polyubiquitin chains. The E3 ubiquitin-proteinligase activity is required for its tumor suppressor function. TheBRCA1-BARD1 heterodimer coordinates a diverse range of cellularpathways such as DNA damage repair, ubiquitination andtranscriptional regulation to maintain genomic stability. Regulatescentrosomal microtubule nucleation. Required for normal cell cycleprogression from G2 to mitosis. Required for appropriate cell cyclearrests after ionizing irradiation in both the S-phase and the G2phase of the cell cycle. Involved in transcriptional regulation ofP21 in response to DNA damage. Required for FANCD2 targeting tosites of DNA damage. May function as a transcriptional regulator.Inhibits lipid synthesis by binding to inactive phosphorylatedACACA and preventing its dephosphorylation. Contributes tohomologous recombination repair (HRR) via its direct interactionwith PALB2, fine-tunes recombinational repair partly through itsmodulatory role in the PALB2-dependent loading of BRCA2-RAD51repair machinery at DNA breaks. Component of the BRCA1-RBBP8complex which regulates CHEK1 activation and controls cell cycleG2/M checkpoints on DNA damage via BRCA1-mediated ubiquitination ofRBBP8.

Subunit:
Heterodimer with BARD1. Part of the BRCA1-associated genome surveillance complex (BASC), which contains BRCA1, MSH2, MSH6, MLH1, ATM, BLM, PMS2 and the RAD50-MRE11-NBN protein complex. This association could be a dynamic process changing throughout the cell cycle and within subnuclear domains. Component of the BRCA1-A complex, at least composed of the BRCA1, BARD1, UIMC1/RAP80, FAM175A/Abraxas, BRCC3/BRCC36, BRE/BRCC45 and BABAM1/NBA1. Interacts (via BRCT domains) with FAM175A/Abraxas and RBBP8. Associates with RNA polymerase II holoenzyme. Interacts with SMC1A and COBRA1/NELFB. Interacts (via BRCT domains) with phosphorylated BRIP1. Interacts with FANCD2 (ubiquitinated). Interacts with BAP1. Interacts with DCLRE1C/Artemis and CLSPN. Interacts with H2AFX (phosphorylated on 'Ser-140'). Interacts with CHEK1 and CHEK2. Interacts with BRCC3. Interacts (via BRCT domains) with ACACA (phosphorylated); the interaction prevents dephosphorylation of ACACA. Interacts with AURKA. Interacts with UBXN1. Part of a trimeric complex containing BRCA1, BRCA2 and PALB2. Interacts with PALB2 and this interaction is essential for its function in HRR. Interacts with BRCA2 only in the presence of PALB2 which serves as the bridging protein.

Subcellular Location:
Cytoplasm; Nucleus. Localizes at sites of DNA damage at double-strand breaks (DSBs) and recruitment to DNA damage sites is mediated by the BRCA1-A complex.

Tissue Specificity:
Isoform 1 and isoform 3 are widely expressed. Isoform 3 is reduced or absent in several breast and ovarian cancer cell lines.

Post-translational modifications:
Phosphorylation at Ser-308 by AURKA is required for normalcell cycle progression from G2 to mitosis. Phosphorylated inresponse to IR, UV, and various stimuli that cause checkpointactivation, probably by ATM or ATR. Phosphorylation at Ser-988 byCHEK2 regulates mitotic spindle assembly.
Autoubiquitinated, undergoes 'Lys-6'-linkedpolyubiquitination. 'Lys-6'-linked polyubiquitination does notpromote degradation.

DISEASE:
Defects in BRCA1 are a cause of susceptibility to breastcancer (BC) [MIM:114480]. A common malignancy originating frombreast epithelial tissue. Breast neoplasms can be distinguished bytheir histologic pattern. Invasive ductal carcinoma is by far themost common type. Breast cancer is etiologically and geneticallyheterogeneous. Important genetic factors have been indicated byfamilial occurrence and bilateral involvement. Mutations at morethan one locus can be involved in different families or even in thesame case. Note=Mutations in BRCA1 are thought to be responsiblefor 45% of inherited breast cancer. Moreover, BRCA1 carriers have a4-fold increased risk of colon cancer, whereas male carriers face a3-fold increased risk of prostate cancer. Cells lacking BRCA1 showdefects in DNA repair by homologous recombination.
Defects in BRCA1 are a cause of susceptibility tofamilial breast-ovarian cancer type 1 (BROVCA1) [MIM:604370]. Acondition associated with familial predisposition to cancer of thebreast and ovaries. Characteristic features in affected familiesare an early age of onset of breast cancer (often before age 50),increased chance of bilateral cancers (cancer that develop in bothbreasts, or both ovaries, independently), frequent occurrence ofbreast cancer among men, increased incidence of tumors of otherspecific organs, such as the prostate. Note=Mutations in BRCA1 arethought to be responsible for more than 80% of inheritedbreast-ovarian cancer.
Defects in BRCA1 are a cause of susceptibility to ovariancancer (OC) [MIM:167000]. The term ovarian cancer definesmalignancies originating from ovarian tissue. Although manyhistologic types of ovarian tumors have been described, epithelialovarian carcinoma is the most common form. Ovarian cancers areoften asymptomatic and the recognized signs and symptoms, even oflate-stage disease, are vague. Consequently, most patients arediagnosed with advanced disease.
Defects in BRCA1 are a cause of susceptibility topancreatic cancer type 4 (PNCA4)

Similarity:
Contains 2 BRCT domains.
Contains 1 RING-type zinc finger.

Database links:

Entrez Gene: 672 Human

Omim: 113705 Human

SwissProt: P38398 Human

Unigene: 194143 Human



Important Note:
This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
版權(quán)所有 2004-2026 www.a6308.cn 北京博奧森生物技術(shù)有限公司
通過國際質(zhì)量管理體系ISO 9001:2015 GB/T 19001-2016    證書編號: 00124Q34771R2M/1100
通過國際醫(yī)療器械-質(zhì)量管理體系ISO 13485:2016 GB/T 42061-2022    證書編號: CQC24QY10047R0M/1100
京ICP備05066980號-1         京公網(wǎng)安備110107000727號
久久国产精品免费网站 | 亚洲欧美国产成人综合不卡 | 国产欧美精品亚洲日本一区 | 欧洲亚洲日韩中文字幕首页 | 米奇奇米777第四色 国产精品免费大片 | 一本一本久久a久久精品66 | 国内精品久久久久久久小说 | 插我一区二区在线观看 | 国产欧美一区二区三区免费 | 天天澡天天添天天摸97影 | 亚洲国产精品特色大片观看完整版 | A级国产乱理伦片在线观看 国产一区二区三区影院 | 国产精品成人一区二区无码欠欠源 | 国产精品内射久久久久欢欢 | 人妻少妇被猛烈进入中文字幕 | 男女无遮挡XX00动态图120秒 | 精品国产麻豆免费人成网站 | 国产欧美日产综合网中文 | 国产AAA片精品网站 打扑克污黄对网站在线看 男女激情射精国产精品久久 | 欧美精品成人一区二区在线观看 | 国产真实老熟女无套内射 | 国产超碰AV人人做人人爽 | 亚洲人成人无码.WWW石榴 | 免费 无码 国产真人视频九色 | 最近免费中文字幕大全高清大全10 | 久久久久精品日韩久久久 | 狠狠色综合7777久夜色撩人 | 欧美日韩精品一区二区在线播放蜜臀 | 国产综合成人久久大片 | 国产手机在线视频 | 日本免费一级婬片A级中文字幕 | 国产精品嫩草影视在线观看 | 97精品国产高清自在线看超 | 久久99人妻无码精品一区二区 | 中文国产成人AⅤ久久 | 内射无码AV-区二区在线观看 | 亚洲精品美女久久久久99 | 亚洲熟妇无码爱V在线观 | 国内久久久久久久久久 | 亚洲欧洲中文日韩久久AV乱码 | 91精品手机国产在线播放 |